Leidos is a recognized global leader in solving important problems in defense, civil, intelligence, homeland security, and health. Explorations in Global Health (ExGloH) is a new division of Leidos Health focused on developing methods that prove effective in not only treating cancer but for safe application in infectious disease vaccines. Building on our deep understanding of infectious disease vaccine development and cancer therapeutics from decades of product development support for our federal customers, we have created an effective platform for discovering novel peptide scaffolds. Our lead candidate has been designed to simultaneously antagonize two members of the CD28 checkpoint receptor family, PD1 and CTLA4.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
A PD1/CTLA4 dual-specific peptide immune modulator
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):